Search company, investor...

Aegerion Pharmaceuticals

aegerion.com

Founded Year

2005

Stage

Asset Sale | AssetsPurchased

Total Raised

$40.11M

About Aegerion Pharmaceuticals

Aegerion Pharmaceuticals is a specialty pharmaceutical company. The company is focused on the development and commercialization of pharmaceuticals to treat cardiovascular and metabolic disease.

Headquarters Location

1 Main St Suite 800

Cambridge, Massachusetts, 02142,

United States

617-945-7968

Missing: Aegerion Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Aegerion Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Aegerion Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Aegerion Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Aegerion Pharmaceuticals Patents

Aegerion Pharmaceuticals has filed 10 patents.

The 3 most popular patent topics include:

  • Syndromes
  • Diabetes
  • Diseases of liver
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/24/2020

12/27/2022

Diseases of liver, Diabetes, Piperidines, Hepatology, Syndromes

Grant

Application Date

1/24/2020

Grant Date

12/27/2022

Title

Related Topics

Diseases of liver, Diabetes, Piperidines, Hepatology, Syndromes

Status

Grant

Latest Aegerion Pharmaceuticals News

Amylyx welcomes former Alnylam exec to help expand Relyvrio; Amarin plugs in an interim chief

Apr 21, 2023

Assistant Editor → Masako Nakamura will lead Relyvrio’s march to key regions as Amylyx’s general manager and head of the Asia Pacific and Latin America international markets. Nakamura, the SVP, head of Asia at Alnylam from 2018-21, tackled a similar gig as GM, Asia with Aegerion Pharmaceuticals and had a 10-year career at Genzyme. Canada approved Amylyx’s ALS drug, known in that country as Albrioza, in June 2022, while the FDA gave it the go-ahead in September following an unconventional second adcomm . Keep reading Endpoints with a free subscription Unlock this story instantly and join 165,700+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Senior Editor More than two years after arriving on the China biopharma scene with a $322 million deal for five of Takeda’s drugs, Hasten Biopharma has landed $315 million to fuel future acquisitions. CBC Group, the investment firm that helped put the company together, is once again headlining the round, joined by Abu Dhabi sovereign wealth fund Mubadala in co-leading a lineup of institutional investors. Hasten is based in Hefei, a five-hour drive to the east from China’s biotech hub in Shanghai, and according to its website, has built a team of more than 700 people since launching in 2020. Keep reading Endpoints with a free subscription Unlock this story instantly and join 165,700+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Senior Editor In a bid to get another PD-1 regimen approved in China, Junshi Biosciences has spelled out Phase III data showing that its drug cut the risk of lung cancer recurrence, progression or death by 60% when added to chemotherapy both before and after surgery. Although Junshi’s toripalimab has yet to be approved in the US — the FDA is still reviewing the candidate after rejecting the first application by Junshi and partner Coherus a year ago — the move is in line with efforts by multinational pharma players to expand the use of PD-(L)1 therapies to earlier lines of treatment. Keep reading Endpoints with a free subscription Unlock this story instantly and join 165,700+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Associate Editor Most of the antibody-drug conjugate talk lately has been centered around Pfizer’s $43 billion deal with Seagen, but Bristol Myers Squibb is looking to up its game in the field by inking a modest upfront for work out of a German biotech. The Big Pharma will pay $22.75 million to Munich-based Tubulis to snag exclusive rights to the startup’s platform to make ADCs for solid tumors. BMS will choose antibody targets and Tubulis will then hand over linker-payloads from its platform to create a matching ADC. Keep reading Endpoints with a free subscription Unlock this story instantly and join 165,700+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Associate Editor Moderna plans to build a “quantum-ready workforce,” in CEO Stéphane Bancel’s words, with the help of global tech conglomerate IBM, the companies said Thursday morning. As the Cambridge, MA-based biotech expands beyond Covid-19 vaccines and into flu, RSV and other disease areas, Moderna plans to employ quantum computing and generative AI to make new mRNA medicines, optimize logistics and do what a “classical computer” can’t. Generative AI is now dinner-party fodder thanks to the arrival of ChatGPT late last year. Keep reading Endpoints with a free subscription Unlock this story instantly and join 165,700+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Associate Editor A day after a leaked data presentation showing positive Phase III results for Legend Biotech’s CAR-T treatment Carvykti, the company said it has raised $200 million in a private stock sale, based on the strength of the data. Legend is partnered with Johnson & Johnson on the cell therapy, which is already approved as a fifth-line treatment for multiple myeloma. Data from the trial showed that Carvykti was associated with a 74% reduction in the risk of multiple myeloma progression or death. Keep reading Endpoints with a free subscription Unlock this story instantly and join 165,700+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Senior Editor No matter how you look at it, the obesity drug market is shaping up to be vast. And the spotlight right now is on Eli Lilly’s tirzepatide, which was approved last year as Mounjaro for type 2 diabetes and is already under rolling submission as an obesity treatment. The current flurry of interest comes in advance of new data expected this month from its second SURMOUNT study at the same time that Mounjaro prescriptions are skyrocketing. Keep reading Endpoints with a free subscription Unlock this story instantly and join 165,700+ biopharma pros reading Endpoints daily — and it's free. SIGN UP News Reporter The UK-based trade union Unite is calling for walkouts at several GSK manufacturing sites due to pay disputes. Unite said Wednesday that hundreds of GSK manufacturing workers will be staging walkouts in May over pay disputes as 750 workers who are members of the trade union have rejected GSK’s pay rate increase, calling it “significantly below inflation rate pay offer. ” GSK has offered a 6% pay increase and a one-time lump sum of £1,300 ($1,616.92), which the pharma said is a package equivalent to a 9.7% increase. GSK said it is disappointed that the union has decided to take action, a company spokesperson emailed to Endpoints News. Keep reading Endpoints with a free subscription Unlock this story instantly and join 165,700+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Senior Editor Two years after the FDA’s controversial approval of Biogen’s Alzheimer’s drug Aduhelm, four of the top agency officials who came under scrutiny for their close relationship with the drugmaker during the approval process have left the agency. Three of those four senior officials, who managed and worked closely with the clinical and biostats reviewers assigned to the Aduhelm application, have now ended up working at drugmakers. The landing spot for the fourth — Billy Dunn, former director of the Division of Neurology Products — has yet to be made public. Keep reading Endpoints with a free subscription Unlock this story instantly and join 165,700+ biopharma pros reading Endpoints daily — and it's free. SIGN UP LOG IN

Aegerion Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Aegerion Pharmaceuticals founded?

    Aegerion Pharmaceuticals was founded in 2005.

  • Where is Aegerion Pharmaceuticals's headquarters?

    Aegerion Pharmaceuticals's headquarters is located at 1 Main St, Cambridge.

  • What is Aegerion Pharmaceuticals's latest funding round?

    Aegerion Pharmaceuticals's latest funding round is Asset Sale.

  • How much did Aegerion Pharmaceuticals raise?

    Aegerion Pharmaceuticals raised a total of $40.11M.

  • Who are the investors of Aegerion Pharmaceuticals?

    Investors of Aegerion Pharmaceuticals include Amryt Pharma, Novelion Therapeutics, Advent International, Medicxi Ventures, Alta Partners and 5 more.

  • Who are Aegerion Pharmaceuticals's competitors?

    Competitors of Aegerion Pharmaceuticals include Bellus Health, Radius, EUSA Pharma, Cornerstone Pharmaceuticals, Xhale, Viamet Pharmaceuticals, Athenex, AkaRx, Salix Pharmaceuticals, Hyperion Therapeutics and 31 more.

Compare Aegerion Pharmaceuticals to Competitors

N
Neuraltus Pharmaceuticals

Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that address critical unmet needs for patients and physicians in the treatment of neurodegenerative diseases. The Company is collaborating with global ALS specialists and seeking input from patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease.

E
ENTRA Pharmaceuticals

ENTRA Pharmaceuticals is a specialty pharmaceutical company developing therapies and improving existing treatments in areas with high unmet medical needs. In addition to the company's technology platform, ENTRA possesses strong expertise in preclinical and clinical drug development and commercialization.

C
Cobrek Pharmaceuticals

Cobrek Pharmaceuticals is engaged in the research, development and commercialization of prescription drug therapies, delivery systems and applications that improve quality of life and enhance the lifestyle of patients across the adolescent and adult age-spectrum with particular attention to the needs of the aging population.

D
Drais Pharmaceuticals

Drais Pharmaceuticals, Inc. is dedicated to the development of therapeutic treatments that address unmet medical needs and provide significant benefits over currently available therapies.

P
Pet Medicus Laboratories

Pet Medicus Laboratories is a specialty pharmaceutical company that is engaged in the formulation, clinical testing, federal registration, manufacture, and sale of drug products for the companion animal market.

I
IVREA Pharmaceuticals

IVREA Pharmaceuticals is a specialty pharmaceutical company focused on clinical development and commercialization of novel prescription pharmaceuticals for the treatment of dermatologic conditions. IVREA's pharmaceuticals leverage topical delivery technologies.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.